Patients with Diffuse Large B-Cell Lymphoma (DLBCL) treated with Tafasitamab (Minjuvi): We Need Your Help!
Lymphoma Canada is preparing a submission for the Canadian Agency for Drugs and Technology (CADTH), and its Quebec equivalent INESSS, for an upcoming drug review on tafasitamab (also referred to as Minjuvi) for relapsed/refractory Diffuse Large B-Cell Lymphoma (DLBCL).
If you have received tafasitamab (also referred to as Minjuvi), you can help by completing our survey! You do not need to live in Canada to complete this survey.
The feedback from this survey will provide valuable patient input required for the submission. CADTH and INESSS use this information to help make recommendations to provinces and territories regarding funding for new cancer drugs.
BY COMPLETING THIS SURVEY, YOU ARE PART OF THE PROCESS THAT MAY HELP PATIENTS GAIN ACCESS TO THIS TREATMENT IN CANADA.
The survey will be open until midnight Pacific Time on Friday, December 3, and should only take between 10-15 minutes of your time.
Take SurveyPlease share and help us spread the word!
